NewAmsterdam Pharma Company N.V.
NAMS
NASDAQ
Healthcare
$34.83
-0.97%loss today
Market position
Market cap rank
#1563
of 2,614
1-day
-0.97%
1-month
+9.84%
6-month
-0.71%
YTD
-1.05%
1-year
+83.70%
5-year
+256.86%
Key figures
Market cap
$4.07B
P/E (live)
—
price ÷ annual EPS
P/E (reported)
-20.0
FY 2025
EPS
-$1.75
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$0.00
Gross margin
99.74%
FY 2025
Operating margin
-1,002.90%
FY 2025
Net margin
-905.74%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$3.52B
FY 2025
EV / EBITDA
-14.54
FY 2025
EV / Sales
156.57
FY 2025
Price / book
5.87
FY 2025
Price / sales
178.34
FY 2025
Earnings yield
-5.08%
FY 2025
FCF yield
-3.69%
FY 2025
Debt / equity
0.00
FY 2025
Current ratio
7.88
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$22.5M
Gross profit
$22.44M
Operating income
$-225.68M
EBITDA
$-242.33M
Net income
$-203.82M
Diluted EPS
-$1.75
Shares outstanding
114,399,326
Trading
Open
$35.27
Previous close
$35.17
Day range
$33.87 – $36.34
52-week range
$19.22 – $42.21
50-day avg
$32.73
200-day avg
$33.61
Volume
1,191,098
Avg volume
1,293,346
Beta
0.08
Price history
+83.70% over 1Y
Compare with peers
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Visit websiteCompany info
CEO
Michael Davidson
IPO date
Feb 9, 2021
Headquarters
Naarden, NH, NL
Country
Fundamentals are annual. Figures labeled with their fiscal year.
